Company news
Nutriband Inc. news in 2025
Nutriband Inc.'s news releases, calls and decks from 2025, newest first.
Nutriband CEO Publishes Letter to Shareholders
December 31, 2025
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
December 29, 2025
Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
December 18, 2025
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
December 18, 2025
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
November 24, 2025
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
October 28, 2025
Nutriband Co-Founder Gareth Sheridan Returns as CEO
October 27, 2025
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
October 10, 2025
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
October 8, 2025
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
October 8, 2025
Nutriband Inc. to Present at the MicroCap Rodeo Conference
September 24, 2025
Nutriband Publishes Q2 Report and Announces Key FDA Meeting for AVERSA™ Fentanyl
September 12, 2025
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
September 10, 2025
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
September 3, 2025
Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025
August 18, 2025
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
August 11, 2025
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
August 8, 2025
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
July 18, 2025
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
July 2, 2025
Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
July 1, 2025
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
June 18, 2025
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
June 9, 2025
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
June 3, 2025
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
June 2, 2025
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
April 11, 2025
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
April 4, 2025
Nutriband Signs Partnership Agreement with Charlotte FC
April 4, 2025
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
February 21, 2025
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
February 12, 2025
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
February 10, 2025
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
February 6, 2025